Clinical Trial Update: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) [Phase 3]

View source ↗

Summary

A Phase 3 trial SEACRAFT-2 evaluating naporafenib plus trametinib in NRAS-mutant melanoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Nras-mutant Melanoma

Drugs mentioned

• Trametinib (trametinib)
• naporafenib (naporafenib)

Snippet

Sponsor: Erasca, Inc. | Conditions: Advanced or Metastatic NRAS-mutant Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING